Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Benzenesulfonic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CureGene Receives Clinical Trial Approval in China for CG-0255 Antiplatelet Therapy
Details : CG-0255 is an advanced P2Y12 receptor antagonist developed as a next-generation antiplatelet therapy, for the treatment of coronary artery disease.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 12, 2024
Lead Product(s) : Benzenesulfonic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable